Structure-based design of Trifarotene (CD5789), a potent and selective RAR gamma agonist for the treatment of acne.Thoreau, E., Arlabosse, J.M., Bouix-Peter, C., Chambon, S., Chantalat, L., Daver, S., Dumais, L., Duvert, G., Feret, A., Ouvry, G., Pascau, J., Raffin, C., Rodeville, N., Soulet, C., Tabet, S., Talano, S., Portal, T.
(2018) Bioorg Med Chem Lett 28: 1736-1741
- PubMed: 29706423
- DOI: https://doi.org/10.1016/j.bmcl.2018.04.036
- Primary Citation of Related Structures:
- PubMed Abstract:
Retinoids have a dominant role in topical acne therapy and to date, only RARβ and RARγ dual agonists have reached the market. Given the tissue distribution of RAR isoforms, it was hypothesized that developing RARγ -selective agonists could yield a new generation of topical acne treatments that would increase safety margins while maintaining the robust efficacy of previous drugs. Structural knowledge derived from the X-ray structure of known γ-selective CD437, suggested the design of a novel triaryl series of agonists which was optimized and ultimately led to the discovery of Trifarotene/CD5789.
Nestlé Skin Health, Les Templiers 2400 Route des Colles, 06410 Biot, France.